drugset / Trial / NCT07258979
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2025-11-05
- Primary completion
- 2028-02
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |
| Subject | YL201 | Other / unclassified | — | Intravenous |